专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP1764091B1 Improvements in or relating to amphoteric liposomes 有权转让
标题翻译：两性脂质体或与两性脂质体相关的改进
公开(公告)号：EP1764091B1
公开(公告)日：2017-08-30
申请号：EP06254821.9
申请日：2006-09-15
申请人： Marina Biotech, Inc.
发明人： Panzner, Steffen , Kerwitz, Yvonne , Rauchhaus, Una , Lutz, Silke , Endert, Gerold
IPC分类号： A61K9/127 , A61P1/00 , A61P1/04 , A61P3/10 , A61P5/16 , A61P11/06 , A61P17/06 , A61P19/02 , A61P25/00 , A61P37/06
CPC分类号： A61K9/1271 , A61K9/0019 , A61K9/127 , A61K9/1272 , A61K31/713 , A61K48/00 , C12N15/1138 , C12N15/88 , C12N2310/11 , C12N2320/32

2. 发明公开

EP2823810A1 Amphoteric liposomes comprising imino lipids 有权转让
标题翻译： Nachahmung von Lipoproteinstrukturen
公开(公告)号：EP2823810A1
公开(公告)日：2015-01-14
申请号：EP14188521.0
申请日：2010-07-02
申请人： Marina Biotech, Inc.
发明人： Panzer, Steffen , Siepi, Evgenios
IPC分类号： A61K9/127 , A61K9/133 , A61K48/00 , C07C401/00 , C07D213/00
摘要： The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charges under physiological conditions, and their use for serum resistant transfection of cells.
摘要翻译：本发明涉及脂质组合物，脂质体具有包含阴离子和阳离子部分的混合物的外表面; 其中阳离子部分的至少一部分是在生理条件下基本上充电的亚氨基部分，以及它们用于血清抗性转染细胞的用途。

3. 发明授权

EP2451440B1 AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS 有权转让
标题翻译：两性与IMINOLIPIDEN脂质体
公开(公告)号：EP2451440B1
公开(公告)日：2014-11-12
申请号：EP10734065.5
申请日：2010-07-02
申请人： Marina Biotech, Inc.
发明人： PANZNER, Steffen , SIEPI, Evgenios
IPC分类号： A61K9/127 , A61K9/133 , A61K48/00
CPC分类号： A61K9/1272 , C07C233/36 , C07C233/43 , C07C237/22 , C07C279/12 , C07C279/14 , C07D213/75 , C07D233/61 , C07J41/0055 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y02P20/582
摘要： The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charges under physiological conditions, and their use for serum resistant transfection of cells.

4. 发明授权

EP1957044B1 AMPHOTERIC LIPOSOME FORMULATION 有权
标题翻译：两性脂质体
公开(公告)号：EP1957044B1
公开(公告)日：2013-03-13
申请号：EP06844698.8
申请日：2006-12-01
申请人： Pronai Therapeutics, Inc. , Marina Biotech, Inc.
发明人： GOODWIN, Neal, Clifford , ENDERT, Gerold , HERZOG, Natalie , KERWITZ, Yvonne , PANZNER, Steffen , RODRIGUEZA, Wendi
IPC分类号： A61K9/127 , C12N15/11
CPC分类号： C12N15/113 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/711 , C12N15/111 , C12N15/1135 , C12N2310/14 , C12N2320/32

5. 发明公开

EP2462924A3 Improvements in or relating to amphoteric liposomes. 审中-公开
标题翻译：改进或与脂质体两性
公开(公告)号：EP2462924A3
公开(公告)日：2013-01-23
申请号：EP12152937.4
申请日：2007-10-12
申请人： Marina Biotech, Inc.
发明人： Panzner, Steffen , Lutz, Silke , Siepi, Evgenios , Muller, Claudia
IPC分类号： A61K9/127
CPC分类号： A61K9/127 , A61K9/1272 , A61K31/713 , Y02P20/582
摘要： An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

6. 发明公开

EP2494993A3 Amino acid lipids and uses thereof 审中-公开
标题翻译：氨基酸脂质及其用途
公开(公告)号：EP2494993A3
公开(公告)日：2012-12-19
申请号：EP12158867.7
申请日：2008-05-02
申请人： Marina Biotech, Inc.
发明人： Quay, Steven , Houston, Michael , Harvie, Pierrot , Adami, Roger , Fam, Renata , Prieve, Mary , Fosnaugh, Kathy , Seth, Shaguna
IPC分类号： A61K48/00 , A61K47/06 , A61K9/127 , C12N15/88 , C07C279/14 , C07D213/40 , C07D233/26 , C12N15/11
CPC分类号： A61K47/183 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/7088 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/44 , A61K48/0025 , A61K48/0033 , C07C235/02 , C07C279/12 , C07C279/14 , C07D213/40 , C07D213/56 , C07D233/26 , C07D233/64 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N15/1138 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y10S514/943
摘要： The present invention provides a compound comprising the structure shown in Formula I for use in delivering a therapeutic nucleic acid, one or more drug agents, or a biologically active agent to a cell,

R 3 -(C=O)-Xaa-Z-R 4 Formula I

wherein
Xaa is histidine, 1-methylhistidine, pyridylalanine, lysine, arginine, homoarginine, nor-norarginine, ornithine, homolysine, asparagine, N ethylasparagine, glutamine, 4-aminophenylalanine, and nor-arginine, or an N-methylated version thereof; R 3 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl;
R 4 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl;
wherein both R 3 and R 4 are lipophilic tails; and
Z is NH, O, S, -CH 2 S-, -CH 2 S(O)-, or an organic linker consisting of 1-40 atoms selected from hydrogen, carbon, oxygen, nitrogen, and sulfur atoms;
and salts thereof.
摘要翻译：本发明提供了包含式I所示结构的化合物，用于将治疗性核酸，一种或多种药物剂或生物活性剂递送至细胞中，R 3 - （C = O）-Xaa-Z-R 4 式I其中Xaa是组氨酸，1-甲基组氨酸，吡啶丙氨酸，赖氨酸，精氨酸，高精氨酸，正 - 精氨酸，鸟氨酸，高赖氨酸，天冬酰胺，N-乙基天冬酰胺，谷氨酰胺，4-氨基苯丙氨酸和正 - 精氨酸或其N-甲基化形式 ; R3独立地为衍生自天然存在或合成的脂质，磷脂，糖脂，三酰甘油，甘油磷脂，鞘脂，神经酰胺，鞘磷脂，脑苷脂或神经节苷脂的亲脂性尾部，其中所述尾部可含有类固醇; 或取代或未取代的C（3-22）烷基，C（6-12）环烷基，C（6-12）环烷基-C（3-22）烷基，C（3-22）烯基，C（3-22 ）炔基，C（3-22）烷氧基或C（6-12）烷氧基-C（3-22）烷基; R4独立地为衍生自天然存在或合成的脂质，磷脂，糖脂，甘油三酯，甘油磷脂，鞘脂，神经酰胺，鞘磷脂，脑苷脂或神经节苷脂的亲脂性尾部，其中尾部可含有类固醇; 或取代或未取代的C（3-22）烷基，C（6-12）环烷基，C（6-12）环烷基-C（3-22）烷基，C（3-22）烯基，C（3-22 ）炔基，C（3-22）烷氧基或C（6-12）烷氧基-C（3-22）烷基; 其中R3和R4都是亲脂性尾部; 和Z是NH，O，S，-CH 2 S - ， - CH 2 S（O） - 或由1-40个选自氢，碳，氧，氮和硫原子的原子组成的有机连接体; 及其盐。

7. 发明公开

EP2468864A1 Nucleic acid compounds for inhibiting VEGF family gene expression and uses thereof 审中-公开
标题翻译： Nukleinsäureverbindungenzur Hemmung der VEGF-Familien-Genexpression und Anwendungen davon
公开(公告)号：EP2468864A1
公开(公告)日：2012-06-27
申请号：EP12153919.1
申请日：2008-02-28
申请人： Marina Biotech, Inc.
发明人： Quay, Steven C. , McSwiggen, James , Vaish, Narendra K. , Ahmadian, Mohammad
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1136 , C12N15/1131 , C12N2310/14 , C12N2310/3231 , C12N2310/533
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.
摘要翻译：本公开提供能够降低或沉默一种或多种VEGF家族基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙隔开的至少两个非重叠的双链区域，其中一条链与一个或多个VEGF家族mRNA互补。此外，meroduplex可以具有至少一个被5-甲基尿苷取代的尿苷和任选的其它修饰或组合。还提供减少细胞或受试者中一种或多种VEGF家族基因表达以治疗一种或多种VEGF家族相关疾病的方法。

8. 发明授权

EP2494993B1 Amino acid lipids and uses thereof 有权
公开(公告)号：EP2494993B1
公开(公告)日：2018-08-01
申请号：EP12158867.7
申请日：2008-05-02
申请人： Marina Biotech, Inc.
发明人： Quay, Steven , Houston, Michael , Harvie, Pierrot , Adami, Roger , Fam, Renata , Prieve, Mary , Fosnaugh, Kathy , Seth, Shaguna
IPC分类号： A61K48/00 , A61K47/06 , A61K9/127 , C12N15/88 , C07C279/14 , C07D213/40 , C07D233/26 , C12N15/11
CPC分类号： A61K47/183 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/7088 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/44 , A61K48/0025 , A61K48/0033 , C07C235/02 , C07C279/12 , C07C279/14 , C07D213/40 , C07D213/56 , C07D233/26 , C07D233/64 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N15/1138 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y10S514/943
摘要： The present invention provides a compound comprising the structure shown in Formula I for use in delivering a therapeutic nucleic acid, one or more drug agents, or a biologically active agent to a cell, €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ R 3 -(C=O)-Xaa-Z-R 4 €ƒ€ƒ€ƒ€ƒ€ƒFormula I wherein Xaa is histidine, 1-methylhistidine, pyridylalanine, lysine, arginine, homoarginine, nor-norarginine, ornithine, homolysine, asparagine, N ethylasparagine, glutamine, 4-aminophenylalanine, and nor-arginine, or an N-methylated version thereof; R 3 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl; R 4 is independently a lipophilic tail derived from a naturally-occurring or synthetic lipid, phospholipid, glycolipid, triacylglycerol, glycerophospholipid, sphingolipid, ceramide, sphingomyelin, cerebroside, or ganglioside, wherein the tail may contain a steroid; or a substituted or unsubstituted C(3-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-C(3-22)alkyl, C(3-22)alkenyl, C(3-22)alkynyl, C(3-22)alkoxy, or C(6-12)alkoxy-C(3-22)alkyl; wherein both R 3 and R 4 are lipophilic tails; and Z is NH, O, S, -CH 2 S-, -CH 2 S(O)-, or an organic linker consisting of 1-40 atoms selected from hydrogen, carbon, oxygen, nitrogen, and sulfur atoms; and salts thereof.

9. 发明公开

EP2496260A1 ACTIVITY GENERATING DELIVERY MOLECULES 审中-公开
标题翻译：活动产生交付分子
公开(公告)号：EP2496260A1
公开(公告)日：2012-09-12
申请号：EP10782465.8
申请日：2010-11-04
申请人： Marina Biotech, Inc.
发明人： FAM, Renata , ADAMI, Roger C. , FOSNAUGH, Kathy L. , HARVIE, Pierrot , JOHNS, Rachel E. , SETH, Shaguna , HOUSTON JR., Michael E. , TEMPLIN, Michael V.
IPC分类号： A61K47/00 , A61K48/00
CPC分类号： A61K31/16 , A61K9/0019 , A61K9/127 , A61K31/401 , A61K31/4172 , A61K31/713 , A61K47/00 , A61K47/18 , A61K47/22 , A61K48/00 , C07C237/52 , C07D207/16 , C07D233/64 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2320/32
摘要： Activity-generating delivery molecules comprising the structure R3—(C═O)-Xaa-NH—R4 wherein Xaa is any D- or L-amino acid residue with a non-hydrogen, substituted or unsubstituted side chain, R3—(C═O)— and —NH—R4 are independently a long chain group, each long chain group containing one or more carbon-carbon double bonds, and salts, compositions and methods of use thereof. The activity-generating delivery compounds and compositions are useful for generating activity of an active agent in a cell, tissue, or subject.
摘要翻译：包含结构R 3-（C = O）-Xaa-NH-R 4的活性产生递送分子，其中Xaa是具有非氢，取代或未取代的侧链的任何D-或L-氨基酸残基，R 3- （C = O） - 和-NH-R 4独立地为长链基团，每个长链基团含有一个或多个碳 - 碳双键，以及它们的盐，组合物和使用方法。产生活性的递送化合物和组合物可用于在细胞，组织或受试者中产生活性剂的活性。

10. 发明公开

EP2451440A1 AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS 有权转让
标题翻译：两性与IMINOLIPIDEN脂质体
公开(公告)号：EP2451440A1
公开(公告)日：2012-05-16
申请号：EP10734065.5
申请日：2010-07-02
申请人： Marina Biotech, Inc.
发明人： PANZNER, Steffen , SIEPI, Evgenios
IPC分类号： A61K9/127 , A61K9/133 , A61K48/00
CPC分类号： A61K9/1272 , C07C233/36 , C07C233/43 , C07C237/22 , C07C279/12 , C07C279/14 , C07D213/75 , C07D233/61 , C07J41/0055 , C12N15/1137 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y02P20/582
摘要： The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式